



HELIXBIOPHARMA

October 10, 2019  
Press Release

9120 Leslie Street, Suite 205  
Richmond Hill, Ontario, L4B 3J9  
Tel: 905-841-2300  
[www.helixbiopharma.com](http://www.helixbiopharma.com)

---

## Helix BioPharma Corp. Board Changes

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced a change in the Company’s Board of Directors.

The Board has accepted the resignation of Mr. Sylwester Cacek’s as director of the Company, effective October 9, 2019. In his place, the Board is pleased to announce the appointment of Mr. Ireneusz Fařara to the Company’s Board. Mr. Fařara has over 30 years of financial institution and industrial sector experience where he steered organizational strategy and built successful teams within diverse businesses. Mr. Fařara has held senior executive roles in organizations such as Bank Gospodarstwa Krajowego and Polish Social Insurance Institution. He also possesses experience in working on various board of directors and supervisory boards of, among others, as General Director at ORLEN Lietuva, member of Supervisory Board PKO BP S.A., Grupa LOTOS S.A., the National Health Fund of Poland. Mr. Fařara graduated from Cracow University of Economics in the field of International Economic Relations.

“On behalf of the Board and Helix management, I would like to thank Mr. Cacek for his time and dedication, and we wish him well in his future endeavors,” said Prof. Sławomir Majewski, Helix’s Chairman of the Board. In addition, we are extremely pleased to welcome Mr. Fařara to Helix’s Board of Directors.

### **About Helix BioPharma Corp.**

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor (“CAR”) based cell therapies. Helix is currently listed on the TSX under the symbol “HBP”.

### **Investor Relations**

Helix BioPharma Corp.  
9120 Leslie Street, Suite 205  
Richmond Hill, Ontario, L4B 3J9  
Tel: 905-841-2300  
Email: [ir@helixbiopharma.com](mailto:ir@helixbiopharma.com)

---